Your new experience awaits. Try the new design now and help us make it even better

RETRACTION article

Front. Pharmacol., 07 November 2025

Sec. Pharmacology of Anti-Cancer Drugs

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1727252

Retraction: Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis

This article is a retraction of:

  1. RETRACTED: Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis

    1. Read original article
Frontiers Editorial Office Frontiers Editorial Office*

A Retraction of the Systematic Review Article
Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis

by Yu J, Meng F, Sui W, Yu J and Shen J (2024) Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Front. Pharmacol. 15:1378577. doi: 10.3389/fphar.2024.1378577

The journal retracts the 4th June 2024 article cited above.

Following concerns regarding the originality of this Frontiers in Pharmacology article, an investigation was conducted in accordance with Frontiers’ policies. It was found that the complaint was valid and that the article should be retracted due to an unacceptable level of similarity to an article published in Frontiers in Immunology on 19th April 2023 by Jinhai Shen, Hui Hou, Bowen Liang, Xiao Guo, Li Chen, Yong Yang, Yun Wang: Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis (Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1155104). Following the Committee on Publication Ethics guidelines, the article published most recently is retracted.

This retraction was approved by the Field Chief Editor of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors have not responded to correspondence regarding this retraction.

Citation: Frontiers Editorial Office (2025) Retraction: Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Front. Pharmacol. 16:1727252. doi: 10.3389/fphar.2025.1727252

Received: 17 October 2025; Accepted: 24 October 2025;
Published: 07 November 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.